Novo Nordisk Bets on CagriSema and Oral Wegovy to Counter Pricing Headwinds and Analysts' Caution

Novo Nordisk enters June with a packed clinical calendar that could either validate its pipeline strategy or expose vulnerabilities, as the stock attempts to claw back from a steep decline. After a 13 percent monthly gain, shares closed at €39.05 on Friday, but the broader picture remains bleak: the equity is down 12.6 percent year-to-date and 35.7 percent over the past twelve months.

The next major test arrives this week at the American Diabetes Association's 86th Scientific Sessions in New Orleans, running from June 5 to 8. Novo Nordisk plans to present 40 abstracts, with the spotlight on Phase 3 data from the REIMAGINE 1–3 studies of CagriSema. This combination of an amylin receptor agonist and a GLP-1 agonist is considered the company's most important near-term pipeline asset. Alongside it, Phase 2 results for Zenagamtide, a once-weekly injection targeting the same dual pathway, will also be unveiled. A dedicated R&D investor webcast is scheduled for June 7 at 4:30 p.m. CDT.

The clinical push comes amid brighter commercial signals. In the United States, the oral formulation of Wegovy (semaglutide) recorded 18,410 prescriptions in its first week, dwarfing Eli Lilly's competing oral Foundayo, which managed 3,707. Critically, roughly 80 percent of oral Wegovy users were previously naive to GLP-1 therapies, suggesting the pill is expanding the addressable patient pool rather than merely cannibalising existing injectables.

European regulatory momentum is also building. France will become the first EU member state to offer standard reimbursement for weight-loss drugs, covering 65 percent of Wegovy's cost from June 15, rising to 100 percent for patients with comorbidities such as hypertension or diabetes. Separately, the CHMP recommended approval of both the Wegovy 25 mg oral tablet and the higher-dose 7.2 mg once-daily pen (Wegovy HD) on May 22. The tablet launch in Europe is slated for the second half of 2026, while the pen arrives in the third quarter, backed by STEP-UP trial data showing an average 20.7 percent weight reduction.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

That pipeline extends far beyond weight management. Novo Nordisk is running Phase 2 and Phase 3 studies for six additional indications, including MASH (a liver disease), Alzheimer's, and chronic kidney disease (CKD). A Food and Drug Administration decision on CKD, based on the FLOW trial, is expected in the second half of 2026. Analysts estimate that these expansions could balloon the GLP-1 market from roughly $50 billion today to more than $130 billion by 2030. Alzheimer's results from the EVOKE+ trial, involving 3,000 patients, will not arrive until 2027.

Financially, the first quarter of 2026 was impressive: revenue climbed to 96.82 billion Danish kroner and net profit to 48.56 billion kroner, compared with 78.09 billion and 29.03 billion in the same period last year. Yet those numbers have done little to lift the stock, which remains nearly 45 percent below its 52-week high of €70.13. The shares have recovered from a March trough of €30.48, and the 50-day moving average now sits comfortably below the current price.

The headwinds are unmistakable. Cheap compounded versions of Wegovy in the United States are eroding pricing power. In response, Novo Nordisk plans to slash Wegovy's list price by roughly 50 percent in January 2027, with corresponding 35 percent reductions for Ozempic and Rybelsus. Analysts at Jefferies and Deutsche Bank have both rated the stock "Hold," with price targets of 270 and 290 Danish kroner respectively. Both houses see little reason to accelerate positioning until the CEO search concludes and the pricing strategy starts to take effect.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

With a trailing price-to-earnings ratio of 10.69, the stock trades well below its five-year median and far from its split-adjusted all-time high of $81.44. The ADA sessions beginning June 5 will show whether CagriSema and Zenagamtide can restore confidence, while the R&D webcast on June 7 offers management a chance to frame the data and set priorities for the second half of the year. The commercial floor is strengthening, but the stock's next move hinges on pipeline conviction.

Ad

Novo Nordisk Stock: New Analysis - 31 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69455131 |